A-485 (Figure 10) was reported as a potent, selective and drug-like catalytic inhibitor of CBP/p300 that competes with acetyl coenzyme A. A-485 selectively inhibits the proliferation of hematological malignancies and AR+ prostate cancer. Here, EP300 is linked to hematologic disorder.